2Lai CL, Chiem RN, Leung NWY,et al. A one-year trial of lamivudine for chronic hepatitis B[J]. Hepatology,1998,339:61-68
3Marinos G, Scaglioni NV, Willians R, et al. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B infection[J]. Hepatology,1996,24:991-995
4Severin A, Liu XY, Wilson JS, et al. Mechanism of duck hepatitis B virus polymerase by (1)-L-2′,3′-dideoxy-3′-thiacytdine[J].Antimicrob Agents Chemother,1995,39:1430-1435
5Boni C, Bertoletti A, Penna A, et al. Lamivodine treatment can restore T cell responsiveness in chronic hepatitis B[J]. J Clin Invest, 1998,102:968-975
6Schiff ER, Karayalcin S, Grimm L, et al. Aplacebo controlled study of lamivudine and interferon α-2b in patients with chronic hepatitis B who previously failed interferon therapy[J]. Hepatology,1998,28:388A(Abstract 901)
7Marrinos G, Scaglioni NV, Williams R, et al. Inpact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B infection[J]. Hepatology,1996,24:991-995
8Multimer D, Naoumov NV, Honkoop P, et al. combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection:Result of a pilot study[J]. J Hepatol,1998,28:923-920
8Castella A, Val lino A, Argentero PA,et al, Preventabi 1 ity of percutaneous injuriesinhealthcare workers: a year- long survey in Italy [ J ]. J Hosp Infect,2003,55 (4) :290 - 294.
